ES444380A1 - Un procedimiento para preparar derivados metalicos antraci- clinicos. - Google Patents

Un procedimiento para preparar derivados metalicos antraci- clinicos.

Info

Publication number
ES444380A1
ES444380A1 ES444380A ES444380A ES444380A1 ES 444380 A1 ES444380 A1 ES 444380A1 ES 444380 A ES444380 A ES 444380A ES 444380 A ES444380 A ES 444380A ES 444380 A1 ES444380 A1 ES 444380A1
Authority
ES
Spain
Prior art keywords
derivatives
glycoside
parent
glycosides
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES444380A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES444380A priority Critical patent/ES444380A1/es
Priority to EG12/77A priority patent/EG12735A/xx
Priority to US05/758,446 priority patent/US4138480A/en
Priority to HU77GO1361A priority patent/HU177832B/hu
Priority to AR266173A priority patent/AR218620A1/es
Priority to DK11877A priority patent/DK11877A/da
Priority to PT66067A priority patent/PT66067B/pt
Priority to AU21319/77A priority patent/AU513698B2/en
Priority to NL7700379A priority patent/NL7700379A/xx
Priority to NZ183084A priority patent/NZ183084A/xx
Priority to FR7701034A priority patent/FR2338285A1/fr
Priority to PH19347A priority patent/PH16582A/en
Priority to IL51264A priority patent/IL51264A/xx
Priority to NO770122A priority patent/NO770122L/no
Priority to DE2701405A priority patent/DE2701405C2/de
Priority to AT19677A priority patent/AT349634B/de
Priority to SE7700398A priority patent/SE7700398L/xx
Priority to SU772439103A priority patent/SU886748A3/ru
Priority to CH48477A priority patent/CH629219A5/de
Priority to FI770115A priority patent/FI770115A/fi
Priority to JP252277A priority patent/JPS52111555A/ja
Priority to CA269,807A priority patent/CA1070680A/en
Priority to PL1977195344A priority patent/PL108660B1/pl
Priority to GR52580A priority patent/GR70696B/el
Priority to GB2367/77A priority patent/GB1568263A/en
Priority to BE174119A priority patent/BE850438A/xx
Priority to DD7700196969A priority patent/DD129452A5/xx
Priority to IE87/77A priority patent/IE44689B1/en
Priority to YU00054/77A priority patent/YU5477A/xx
Publication of ES444380A1 publication Critical patent/ES444380A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR DERIVADOS METALICOS ANTRACICLINICOS DE FE3+, CU2+, NI2+, CO2+, FE2+, ZN2+, CD2+, PB2+, AL3+ HG2+. EL ANTIBIOTICO DAUNORUBICINA O EL DOXORUBICINA SE HACE REACCIONAR CON UN CLORURO, SULFATO, NITRATO U OTRA SAL DE LOS METALES ANTERIORES. LA REACCION SE LLEVA A CABO EN MEDIO ACUOSO A TEMPERATURA DE 15 A 50 GRADOS C Y A UN PH NEUTRO O PROXIMO A LA NEUTRALIDAD. LA PROPORCION METAL ANTIBIOTICO ES 1:1, 2:1, 3:1, 4:1, METAL EN EXCESO O METAL EN OTRA FRACCION SUPERIOR A 1:1. LOS DERIVADOS METALICOS OBTENIDOS SE UTILIZAN EN LA QUIMIOTERAPIA ANTICANCEROSA.
ES444380A 1976-01-16 1976-01-16 Un procedimiento para preparar derivados metalicos antraci- clinicos. Expired ES444380A1 (es)

Priority Applications (29)

Application Number Priority Date Filing Date Title
ES444380A ES444380A1 (es) 1976-01-16 1976-01-16 Un procedimiento para preparar derivados metalicos antraci- clinicos.
EG12/77A EG12735A (en) 1976-01-16 1977-01-08 Process for preparing of metal chelate derivatives of anthracychine
US05/758,446 US4138480A (en) 1976-01-16 1977-01-11 Novel anthracycline glycosides and methods of preparing the same
HU77GO1361A HU177832B (en) 1976-01-16 1977-01-11 Process for producing new antracycline glucisides
AR266173A AR218620A1 (es) 1976-01-16 1977-01-12 Metodo para preparar nuevos derivados ferricos de doxorrubicina
DK11877A DK11877A (da) 1976-01-16 1977-01-13 Antracyklinglykosider og fremgangsmade til fremstilling deraf
PT66067A PT66067B (en) 1976-01-16 1977-01-13 Process for preparing novel anthracycline glycosides
AU21319/77A AU513698B2 (en) 1976-01-16 1977-01-13 Anthracycline glycosides
NL7700379A NL7700379A (nl) 1976-01-16 1977-01-14 Werkwijze ter bereiding van anthracyclinegly- cosiden, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
NZ183084A NZ183084A (en) 1976-01-16 1977-01-14 Metal chelates or daunorubicin and doxorubicin and pharmaceutical compositions
FR7701034A FR2338285A1 (fr) 1976-01-16 1977-01-14 Nouveaux derives de glycosides d'anthracycline et procede pour les preparer
PH19347A PH16582A (en) 1976-01-16 1977-01-14 Novel anthracycline glycosides and methods of preparing the same
IL51264A IL51264A (en) 1976-01-16 1977-01-14 Metal derivatives of anthracycline glycoside antibiotics
NO770122A NO770122L (no) 1976-01-16 1977-01-14 Nye antracyklinglykosider og fremgangsm}te for fremstilling av dette.
DE2701405A DE2701405C2 (de) 1976-01-16 1977-01-14 Triferridoxorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltendes pharmazeutisches Mittel
AT19677A AT349634B (de) 1976-01-16 1977-01-14 Verfahren zur herstellung von neuen anthra- cyclinglycosiden
SE7700398A SE7700398L (sv) 1976-01-16 1977-01-14 Antracyklinderivat och forfarande for framstellning derav
SU772439103A SU886748A3 (ru) 1976-01-16 1977-01-14 Способ получени антрациклиновых гликозидов
CH48477A CH629219A5 (de) 1976-01-16 1977-01-14 Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten.
FI770115A FI770115A (es) 1976-01-16 1977-01-14
JP252277A JPS52111555A (en) 1976-01-16 1977-01-14 Novel anthracycline glycoside
CA269,807A CA1070680A (en) 1976-01-16 1977-01-14 Anthracycline glycosides and methods of preparing the same
PL1977195344A PL108660B1 (en) 1976-01-16 1977-01-15 Method of producing new metallic derivatives of anthracycline glycosides
GR52580A GR70696B (es) 1976-01-16 1977-01-15
GB2367/77A GB1568263A (en) 1976-01-16 1977-01-17 Metallic chelates of daunorubicin and doxorubicin
BE174119A BE850438A (fr) 1976-01-16 1977-01-17 Nouveaux derives de glycosides d'enthracycline et procede pour les preparer
DD7700196969A DD129452A5 (de) 1976-01-16 1977-01-17 Neue anthracyclinglycoside und verfahren zu deren herstellung
IE87/77A IE44689B1 (en) 1976-01-16 1977-01-17 Metallic chelates of daunorubicin and doxorubicin
YU00054/77A YU5477A (en) 1976-01-16 1977-03-21 Improved lock for a door with front closing process for obtaining new anthracyclin glucosides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES444380A ES444380A1 (es) 1976-01-16 1976-01-16 Un procedimiento para preparar derivados metalicos antraci- clinicos.

Publications (1)

Publication Number Publication Date
ES444380A1 true ES444380A1 (es) 1977-06-16

Family

ID=8470743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES444380A Expired ES444380A1 (es) 1976-01-16 1976-01-16 Un procedimiento para preparar derivados metalicos antraci- clinicos.

Country Status (29)

Country Link
US (1) US4138480A (es)
JP (1) JPS52111555A (es)
AR (1) AR218620A1 (es)
AT (1) AT349634B (es)
AU (1) AU513698B2 (es)
BE (1) BE850438A (es)
CA (1) CA1070680A (es)
CH (1) CH629219A5 (es)
DD (1) DD129452A5 (es)
DE (1) DE2701405C2 (es)
DK (1) DK11877A (es)
EG (1) EG12735A (es)
ES (1) ES444380A1 (es)
FI (1) FI770115A (es)
FR (1) FR2338285A1 (es)
GB (1) GB1568263A (es)
GR (1) GR70696B (es)
HU (1) HU177832B (es)
IE (1) IE44689B1 (es)
IL (1) IL51264A (es)
NL (1) NL7700379A (es)
NO (1) NO770122L (es)
NZ (1) NZ183084A (es)
PH (1) PH16582A (es)
PL (1) PL108660B1 (es)
PT (1) PT66067B (es)
SE (1) SE7700398L (es)
SU (1) SU886748A3 (es)
YU (1) YU5477A (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959798A (en) * 1958-03-24 1960-11-15 Champlin Oil & Refining Co Pipe line cleaner
US4337335A (en) * 1978-05-18 1982-06-29 Schering Corporation Transition metal salt complexes of polyamino organic compounds
IT1184161B (it) * 1985-03-14 1987-10-22 Franco Conti Derivati del chitosano costituiti da complessi di coordinazione con ioni ferrosi
JPS63310830A (ja) * 1987-06-10 1988-12-19 Meiji Seika Kaisha Ltd 抗レトロウイルス剤
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
NL1009226C2 (nl) * 1998-05-20 1999-11-24 Faculteit Geneeskunde Universi Toepassing van een nucleïnezuur-bindend chemotherapeutisch agens, een farmaceutisch preparaat en een geneesmiddelcombinatie.
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
EP1817004A2 (en) * 2004-11-15 2007-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
US9512485B2 (en) 2010-08-24 2016-12-06 Dana-Farber Cancer Institute. Inc. Methods for predicting anti-cancer response
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
EP2794907B2 (en) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
NZ712663A (en) 2013-04-05 2021-07-30 Myriad Genetics Inc Methods and materials for assessing homologous recombination deficiency
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2016025958A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074927A (en) * 1960-04-12 1963-01-22 Paul D Saltman Metallic complexes of reducing sugars
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1469430A (en) * 1974-12-24 1977-04-06 Farmaceutici Italia Daunomycin derivatives

Also Published As

Publication number Publication date
PT66067A (en) 1977-02-01
SU886748A3 (ru) 1981-11-30
AT349634B (de) 1979-04-10
DK11877A (da) 1977-07-17
YU5477A (en) 1982-06-30
BE850438A (fr) 1977-05-16
DE2701405A1 (de) 1977-07-21
ATA19677A (de) 1978-09-15
FR2338285A1 (fr) 1977-08-12
JPS52111555A (en) 1977-09-19
CH629219A5 (de) 1982-04-15
US4138480A (en) 1979-02-06
FI770115A (es) 1977-07-17
IL51264A (en) 1980-05-30
NL7700379A (nl) 1977-07-19
GR70696B (es) 1982-12-30
AU513698B2 (en) 1980-12-18
NZ183084A (en) 1980-04-28
GB1568263A (en) 1980-05-29
DD129452A5 (de) 1978-01-18
PT66067B (en) 1978-06-23
PH16582A (en) 1983-11-22
FR2338285B1 (es) 1980-03-14
AR218620A1 (es) 1980-06-30
CA1070680A (en) 1980-01-29
DE2701405C2 (de) 1986-02-27
EG12735A (en) 1981-03-31
NO770122L (no) 1977-07-19
HU177832B (en) 1981-12-28
JPS6133039B2 (es) 1986-07-31
IE44689B1 (en) 1982-02-24
IL51264A0 (en) 1977-03-31
PL108660B1 (en) 1980-04-30
PL195344A1 (pl) 1978-08-14
SE7700398L (sv) 1977-07-17
AU2131977A (en) 1978-07-20
IE44689L (en) 1977-07-16

Similar Documents

Publication Publication Date Title
ES444380A1 (es) Un procedimiento para preparar derivados metalicos antraci- clinicos.
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
CA2001765A1 (en) Chelants possessing ortho ligating functionality and complexes thereof
Vecchi et al. Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate
Carbone et al. Endometrial cancer: approach to development of effective chemotherapy
Boven et al. The anti-tumour effects of the prodrugs Nl-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts
Nagase et al. Effects of Intralesional Versus Ip Administration of Cisplatin on Squamous Cell Carcinoma of Mice 1, 2
Morinaga et al. Ciliated‐cell adenocarcinoma of the pancreas
Dawson Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice
Kobayashi et al. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma
Pratesi et al. Antitumor Activity of N-trifluoroacetyladriamycin-14-valerate¹
Schütte et al. 4′-Epi-doxorubicin—A clinical phase-II trial in solid tumors
Rutz et al. Strategies for the prevention of treatment-induced secondary cancer
Muggia et al. The anthracycline antibiotics: New directions in drug development and cancer treatment
WO2002022159A8 (en) Thionin as an antineoplastic and immunostimulant
Wils Epirubicin in advanced gastrointestinal (GI) cancer
Cortes-Funes et al. Quelamycin: A summary of phase I clinical trials
D'Angio et al. Relapse patterns and survival of postoperatively irradiated and non-irradiated locally advanced wilms' tumor patients. A report of the national wilms' tumor study (NWTS)
Stratton et al. Depressed natural killer cell activity in tumor-bearing rats: effect of immunotherapy and cytoreductive chemotherapy
Glynne-Jones et al. The ‘urn’portal; An alternative to the ‘mantle’portal in the chemoradiotherapy management of paediatric Hodgkin's disease
Struck Antineoplastic Agents
WO1991001757A1 (en) Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
Hays Wilms' tumor: Natural history and prognostic factors. A retrospective study of 248 cases treated at the institut-gustave-roussy 1952–1967: J. Lemerle, F. Tournade, R. Gerard-Marchant, R. Flamant, D. Sarrazin, F. Flamant, M. Lemerle, S. Jundt, J. Zucker, and O. Schweisguth. Cancer 37: 2557–66,(May) 1976
Dougall The changing management of nephrobolastoma: AW Wilkinson. J. Roy. Coll. Surg. Edinb. 21: 120–129 (March) 1976
Özkan et al. 604Analysis of prognostic factors in advanced non-small cell lung cancer